These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 17174068)

  • 1. A developmental comparison of the neurobehavioral effects of ecstasy (MDMA).
    Piper BJ
    Neurotoxicol Teratol; 2007; 29(2):288-300. PubMed ID: 17174068
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Are there sex differences associated with the effects of ecstasy/3,4-methylenedioxymethamphetamine (MDMA)?
    Allott K; Redman J
    Neurosci Biobehav Rev; 2007; 31(3):327-47. PubMed ID: 17109962
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term neuropsychiatric consequences of "ecstasy" (MDMA): a review.
    Montoya AG; Sorrentino R; Lukas SE; Price BH
    Harv Rev Psychiatry; 2002; 10(4):212-20. PubMed ID: 12119307
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Motor delays in MDMA (ecstasy) exposed infants persist to 2 years.
    Singer LT; Moore DG; Min MO; Goodwin J; Turner JJ; Fulton S; Parrott AC
    Neurotoxicol Teratol; 2016; 54():22-8. PubMed ID: 26806601
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adverse reactions with 3,4-methylenedioxymethamphetamine (MDMA; 'ecstasy').
    McCann UD; Slate SO; Ricaurte GA
    Drug Saf; 1996 Aug; 15(2):107-15. PubMed ID: 8884162
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A review of the mechanisms involved in the acute MDMA (ecstasy)-induced hyperthermic response.
    Green AR; O'shea E; Colado MI
    Eur J Pharmacol; 2004 Oct; 500(1-3):3-13. PubMed ID: 15464016
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is there a case for MDMA-assisted psychotherapy in the UK?
    Sessa B
    J Psychopharmacol; 2007 Mar; 21(2):220-4. PubMed ID: 17329304
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Developmental outcomes of 3,4-methylenedioxymethamphetamine (ecstasy)-exposed infants in the UK.
    Singer LT; Moore DG; Min MO; Goodwin J; Turner JJ; Fulton S; Parrott AC
    Hum Psychopharmacol; 2015 Jul; 30(4):290-4. PubMed ID: 26216565
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Altered neuroendocrine and behavioral responses to m-chlorophenylpiperazine in 3,4-methylenedioxymethamphetamine (MDMA) users.
    McCann UD; Eligulashvili V; Mertl M; Murphy DL; Ricaurte GA
    Psychopharmacology (Berl); 1999 Nov; 147(1):56-65. PubMed ID: 10591869
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The dark side of ecstasy: neuropsychiatric symptoms after exposure to 3,4-methylenedioxymethamphetamine.
    Karlsen SN; Spigset O; Slørdal L
    Basic Clin Pharmacol Toxicol; 2008 Jan; 102(1):15-24. PubMed ID: 18047478
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An exploration of the history and controversies surrounding MDMA and MDA.
    Pentney AR
    J Psychoactive Drugs; 2001; 33(3):213-21. PubMed ID: 11718314
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Syllogistic reasoning performance in MDMA (Ecstasy) users.
    Montgomery C; Fisk JE; Newcombe R; Wareing M; Murphy PN
    Exp Clin Psychopharmacol; 2005 May; 13(2):137-45. PubMed ID: 15943546
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ethanol, 3,4-methylenedioxymethamphetamine (ecstasy) and their combination: long-term behavioral, neurochemical and neuropharmacological effects in the rat.
    Cassel JC; Riegert C; Rutz S; Koenig J; Rothmaier K; Cosquer B; Lazarus C; Birthelmer A; Jeltsch H; Jones BC; Jackisch R
    Neuropsychopharmacology; 2005 Oct; 30(10):1870-82. PubMed ID: 15785779
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neurotoxicity of methylenedioxyamphetamines (MDMA; ecstasy) in humans: how strong is the evidence for persistent brain damage?
    Gouzoulis-Mayfrank E; Daumann J
    Addiction; 2006 Mar; 101(3):348-61. PubMed ID: 16499508
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Memory performance in polyvalent MDMA (ecstasy) users who continue or discontinue MDMA use.
    Gouzoulis-Mayfrank E; Fischermann T; Rezk M; Thimm B; Hensen G; Daumann J
    Drug Alcohol Depend; 2005 Jun; 78(3):317-23. PubMed ID: 15893163
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neuropsychological effects of 3,4-methylenedioxymethamphetamine (MDMA or ecstasy) in recreational users.
    Back-Madruga C; Boone KB; Chang L; Grob CS; Lee A; Nations H; Poland RE
    Clin Neuropsychol; 2003 Nov; 17(4):446-59. PubMed ID: 15168910
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dark Classics in Chemical Neuroscience: 3,4-Methylenedioxymethamphetamine.
    Dunlap LE; Andrews AM; Olson DE
    ACS Chem Neurosci; 2018 Oct; 9(10):2408-2427. PubMed ID: 30001118
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ecstasy related periodontitis and mucosal ulceration -- a case report.
    Brazier WJ; Dhariwal DK; Patton DW; Bishop K
    Br Dent J; 2003 Feb; 194(4):197-9. PubMed ID: 12627194
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is ecstasy MDMA? A review of the proportion of ecstasy tablets containing MDMA, their dosage levels, and the changing perceptions of purity.
    Parrott AC
    Psychopharmacology (Berl); 2004 May; 173(3-4):234-41. PubMed ID: 15007594
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patterns of memory dysfunction in current and 2-year abstinent MDMA users.
    Ward J; Hall K; Haslam C
    J Clin Exp Neuropsychol; 2006 Apr; 28(3):306-24. PubMed ID: 16618622
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.